Cancer Program
Cancer remains one of the world’s greatest health challenges. BioShift’s cancer research program focuses on early detection and metabolic treatment.
Early detection
Using advanced protein-based testing our liquid biopsy aims to detect cancer at its earliest stages and potentially identify where it begins.
Metabolic treatments
In parallel, our team studies metabolic therapies that can disrupt the unique way cancer cells produce and use energy — targeting the disease while protecting healthy cells.
Contributions to this program strengthens efforts to refine early diagnostic testing and investigate safe, targeted therapeutic strategies. Your support helps sustain the laboratory research, validation studies, and data analysis that moves this project forward.
-
BioShift is developing a protein-based liquid biopsy that detects the subtle blood protein changes associated with early cancers. This approach moves beyond DNA risk screening to identify cancer before imaging can detect it — allowing for earlier, potentially life-saving intervention.
-
Cancer cells rely on distinct energy pathways that differ from normal cells. BioShift’s studies examine how to selectively disrupt these metabolic processes, limit tumor growth, and helping restore cells’ normal function.
